News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,084 Results
Type
Article (38931)
Company Profile (275)
Press Release (642878)
Section
Business (203792)
Career Advice (1983)
Deals (35354)
Drug Delivery (83)
Drug Development (80759)
Employer Resources (168)
FDA (16079)
Job Trends (14792)
News (344395)
Policy (32427)
Tag
Academia (2530)
Alliances (49021)
Alzheimer's disease (1185)
Approvals (15997)
Artificial intelligence (109)
Bankruptcy (352)
Best Places to Work (11420)
Biotechnology (195)
Breast cancer (92)
Cancer (809)
Career advice (1653)
Cell therapy (184)
Clinical research (63737)
Collaboration (279)
Compensation (154)
COVID-19 (2515)
Cystic fibrosis (78)
Data (711)
Diabetes (120)
Diagnostics (6065)
Drug pricing (73)
Earnings (83883)
Employer resources (145)
Events (108521)
Executive appointments (225)
FDA (16470)
Funding (255)
Gene therapy (136)
GLP-1 (547)
Government (4313)
Healthcare (18644)
Infectious disease (2580)
Inflammatory bowel disease (98)
Interviews (306)
IPO (16245)
Job creations (3622)
Job search strategy (1414)
Layoffs (406)
Legal (7847)
Lung cancer (142)
Manufacturing (139)
Medical device (13115)
Medtech (13120)
Mergers & acquisitions (19085)
Metabolic disorders (333)
Neuroscience (1410)
NextGen Class of 2024 (6486)
Non-profit (4461)
Northern California (1086)
Obesity (201)
Opinion (175)
Patents (89)
People (56061)
Phase I (19756)
Phase II (28060)
Phase III (20968)
Pipeline (184)
Postmarket research (2553)
Preclinical (8403)
Radiopharmaceuticals (234)
Rare diseases (171)
Real estate (5887)
Regulatory (21399)
Research institute (2306)
Resumes & cover letters (348)
Southern California (1004)
Startups (3560)
United States (10720)
Vaccines (520)
Weight loss (151)
Date
Today (156)
Last 7 days (581)
Last 30 days (2662)
Last 365 days (36085)
2024 (29185)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54088)
2019 (46541)
2018 (35019)
2017 (32112)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (183)
Asia (36950)
Australia (6023)
California (2475)
Canada (1122)
China (190)
Colorado (107)
Connecticut (106)
Europe (79072)
Florida (354)
Georgia (88)
Illinois (293)
Indiana (167)
Kansas (95)
Maryland (480)
Massachusetts (2004)
Michigan (140)
Minnesota (241)
New Jersey (743)
New York (761)
North Carolina (639)
Northern California (1086)
Ohio (120)
Pennsylvania (712)
South America (1091)
Southern California (1004)
Texas (340)
Utah (71)
Washington State (292)
682,084 Results for "vaxart inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23, 2024
Vaxart, Inc. announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.
May 23, 2024
·
2 min read
Biotech Bay
Vaxart Provides Business Update - June 17, 2024
Vaxart, Inc. provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.
June 17, 2024
·
8 min read
Biotech Bay
Vaxart Announces $40 Million Underwritten Offering of Common Stock
Vaxart, Inc. announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share.
June 13, 2024
·
3 min read
Drug Development
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate.
April 30, 2024
·
7 min read
Deals
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024.
March 20, 2024
·
5 min read
Business
Vaxart, Inc. Announces Management Change - Jan 16, 2024
Vaxart, Inc. announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Vaxart as President, Chief Executive Officer, and Director on Vaxart’s Board of Directors.
January 16, 2024
·
5 min read
Business
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the first quarter of 2024.
May 13, 2024
·
10 min read
Business
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Vaxart, Inc. announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024.
March 6, 2024
·
6 min read
Press Releases
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 30, 2024
September 2, 2024
·
2 min read
Drug Development
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Vaxart, Inc. announced that it received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle.
June 13, 2024
·
8 min read
1 of 68,209
Next
